Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 22,258 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Healthy Volunteer
Interventions: Part 1: SAD RO7033877, Part 1: SAD placebo, Part 2: Treatment A, RO7033877, Part 2: Treatment B, RO7033877, Part 2: Treatment C, moxifloxacin, Part 2: Treatment D, RO7033877 and moxifloxacin placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Pancreas Cancer
Interventions: TG01 Vaccine, QS-21, Balstilimab; Biological · Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Fairway, Kansas • Overland Park, Kansas • Westwood, Kansas + 2 more

Conditions: Substance-Related Disorders
Interventions: Standard letter, Comparator letter; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Small Cell Lung Cancer
Interventions: Alisertib, Placebo, Paclitaxel; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 21
States / cities: Los Angeles, California • Sacramento, California • New Haven, Connecticut + 18 more

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Type II
Interventions: Diabetes Knowledge/Information, Motivation/Behavioral Skills, Combined Intervention, Usual Care; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Pulmonary Arterial Hypertension
Interventions: HS235, Placebo; Biological · Other
Lead sponsor: 35Pharma Inc., a GSK company; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Tampa, Florida • Boston, Massachusetts • Providence, Rhode Island

Conditions: Coronary Artery Bypass Graft Surgery, Atherosclerosis, Vein Occlusion
Interventions: Evolocumab, Placebo; Drug · Other
Lead sponsor: Unity Health Toronto; Other
Eligibility: 18 Years and older
Enrollment: 782 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 5
States / cities: San Francisco, California • Jacksonville, Florida • Portland, Maine + 2 more

Conditions: Hypercholesterolemia
Interventions: Disodium Ascorbyl Phytostanol Phosphate (FM-VP4); Drug
Lead sponsor: Forbes Medi-Tech; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Timeline: Started 2005
U.S. locations: 14
States / cities: Mobile, Alabama • San Diego, California • Daytona Beach, Florida + 10 more

Conditions: Multiple Sclerosis, Fatigue, Insomnia
Interventions: Suvorexant, Placebo; Drug
Lead sponsor: Theodore R. Brown, MD MPH; Other
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Kirkland, Washington

Conditions: Insulin Resistance
Interventions: Hi-maize starch (Low dose), Hi-maize starch (High-dose), Control (starch); Other
Lead sponsor: Ingredion Incorporated; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Glen Ellyn, Illinois

Conditions: Autoimmune Hepatitis, AIH
Interventions: Inebilizumab, Placebo, Standard of Care; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 12
States / cities: Little Rock, Arkansas • Rialto, California • Valencia, California + 9 more

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: Celecoxib; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 875 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 67
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 58 more

Conditions: Depressive Disorder
Interventions: Carbidopa/levodopa, Placebo, Exercise training, Control; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 60 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Severe Head Trauma
Interventions: AbelaDrug200, mannitol; Drug
Lead sponsor: Abela Pharmaceuticals, Inc.; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Irvine, California • Boston, Massachusetts • Columbus, Ohio

Conditions: Healthy Participants
Interventions: BMS-986278, Sildenafil, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Cypress, California • Miami, Florida

Conditions: Lung Carcinoma
Interventions: Screening Questionnaire Administration, X-Ray Imaging; Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 55 Years to 74 Years
Enrollment: 154,901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glabellar Lines
Interventions: AGN-151586, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Fremont, California • Santa Monica, California • Miami, Florida + 6 more

Conditions: Epilepsy
Interventions: ataluren, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 2 Years to 12 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure, Left Ventricular Systolic Dysfunction
Interventions: Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 29 Days to 17 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 20
States / cities: Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more

Conditions: Wheezing, Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Phoenix, Arizona • Destin, Florida • Miami, Florida + 11 more

Conditions: Alcohol Abuse, Cognitive Deficit in Attention
Interventions: Koru Mindfulness (KM) Training, Navigating College (NC) Training; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 19 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Olanzapine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 33
States / cities: Anaheim, California • National City, California • Orange, California + 30 more

Conditions: COVID-19, Lung Infection
Interventions: Opaganib, Placebo; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Mucocutaneous Lymph Node Syndrome, Kawasaki Disease
Interventions: Etanercept, Placebo; Drug
Lead sponsor: Michael Portman; Other
Eligibility: 2 Months to 20 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 7
States / cities: New Hyde Park, New York • New York, New York • The Bronx, New York + 4 more

Search by objective public record fields.

A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval

Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer

Encouraging Judicious Prescribing of Opioids in Los Angeles County

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM

A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults

Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery

Study on the Safety and Effects on Lipids of FM-VP4 in Subjects With Primary Hypercholesterolemia

A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

Effects of Hi-maize Resistant Starch on Insulin Sensitivity

A Trial of Inebilizumab in Participants With Autoimmune Hepatitis

Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"

Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing

Controlled Trial of ABELADRUG200 in Closed, Severe Head Injury

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

Screening for Lung Cancer in Older Patients (PLCO Screening Trial)

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

Pilot Study on Training Emerging Adults Skills in Navigating College

Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease